Champions Oncology, Inc.
CSBR
$7.63
$0.222.97%
NASDAQ
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -27.49% | 26.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -27.49% | 26.32% | |||
| Cost of Revenue | 9.88% | -10.92% | |||
| Gross Profit | -51.22% | 71.95% | |||
| SG&A Expenses | 15.01% | 15.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.19% | -1.70% | |||
| Operating Income | -138.10% | 514.62% | |||
| Income Before Tax | -143.47% | 511.37% | |||
| Income Tax Expenses | -660.87% | 109.09% | |||
| Earnings from Continuing Operations | -140.82% | 517.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -140.82% | 517.45% | |||
| EBIT | -138.10% | 514.62% | |||
| EBITDA | -126.96% | 332.98% | |||
| EPS Basic | -140.66% | 512.13% | |||
| Normalized Basic EPS | -136.83% | 506.18% | |||
| EPS Diluted | -143.03% | 520.00% | |||
| Normalized Diluted EPS | -138.61% | 495.76% | |||
| Average Basic Shares Outstanding | 0.39% | 0.79% | |||
| Average Diluted Shares Outstanding | -4.26% | 2.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||